Show simple item record

Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose

dc.rights.licenseopenen_US
dc.contributor.authorPALMSTEN, K.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorROLLAND, Matthieu
dc.contributor.authorHEBERT, M. F.
dc.contributor.authorCLOWSE, M. E. B.
dc.contributor.authorSCHATZ, M.
dc.contributor.authorXU, R.
dc.contributor.authorCHAMBERS, C. D.
dc.date.accessioned2020-12-14T09:52:39Z
dc.date.available2020-12-14T09:52:39Z
dc.date.issued2018-04
dc.identifier.issn1099-1557 (Electronic) 1053-8569 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/21428
dc.description.abstractEnPURPOSE: To characterize prednisone use in pregnant women with rheumatoid arthritis using individual-level heat-maps and clustering individual trajectories of prednisone dose, and to evaluate the association between prednisone dose trajectory groups and gestational length. METHODS: This study included pregnant women with rheumatoid arthritis who enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study (2003-2014) before gestational week 20 and reported prednisone use without another oral glucocorticoid during pregnancy (n = 254). Information on medication use and pregnancy outcomes was collected by telephone interview plus by medical record review. Prednisone daily dose and cumulative dose were plotted by gestational day using a heat map for each individual. K-means clustering was used to cluster individual trajectories of prednisone dose into groups. The associations between trajectory group and demographics, disease severity measured by the Health Assessment Questionnaire at enrollment, and gestational length were evaluated. RESULTS: Women used prednisone 3 to 292 days during pregnancy, with daily doses ranging from <1 to 60 mg. Total cumulative dose ranged from 8 to 6225 mg. Disease severity, non-biologic disease modifying anti-rheumatic drug use, and gestational length varied significantly by trajectory group. After adjusting for disease severity, non-biologic disease modifying anti-rheumatic drug use, and other covariates, the highest vs lowest daily dose trajectory group was associated with reduced gestational age at delivery (beta: -2.3 weeks (95%: -3.4, -1.3)), as was the highest vs lowest cumulative dose trajectory group (beta: -2.6 weeks (95%: -3.6, -1.5)). CONCLUSIONS: In pregnant women with rheumatoid arthritis, patterns of higher prednisone dose were associated with shorter gestational length compared with lower dose.
dc.language.isoENen_US
dc.title.enPatterns of prednisone use during pregnancy in women with rheumatoid arthritis: Daily and cumulative dose
dc.title.alternativePharmacoepidemiol Drug Safen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/pds.4410en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29488292en_US
bordeaux.journalPharmacoepidemiology and Drug Safetyen_US
bordeaux.page430-438en_US
bordeaux.volume4en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03063495
hal.version1
hal.date.transferred2020-12-14T09:52:44Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Pharmacoepidemiology%20and%20Drug%20Safety&amp;rft.date=2018-04&amp;rft.volume=4&amp;rft.spage=430-438&amp;rft.epage=430-438&amp;rft.eissn=1099-1557%20(Electronic)%201053-8569%20(Linking)&amp;rft.issn=1099-1557%20(Electronic)%201053-8569%20(Linking)&amp;rft.au=PALMSTEN,%20K.&amp;ROLLAND,%20Matthieu&amp;HEBERT,%20M.%20F.&amp;CLOWSE,%20M.%20E.%20B.&amp;SCHATZ,%20M.&amp;rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record